Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE COST-EFFECTIVENESS OF CLOZAPINE - A SURVEY OF THE LITERATURE
Autore:
MORRIS S; HOGAN T; MCGUIRE A;
Indirizzi:
CITY UNIV LONDON,DEPT ECON,NORTHAMPTON SQ LONDON EC1V 0HB ENGLAND NOVARTIS PHARMA AG,HLTH ECON DEPT BASEL SWITZERLAND
Titolo Testata:
Clinical drug investigation
fascicolo: 2, volume: 15, anno: 1998,
pagine: 137 - 152
SICI:
1173-2563(1998)15:2<137:TCOC-A>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; REFRACTORY SCHIZOPHRENIA; INDUCED AGRANULOCYTOSIS; BENEFITS; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
40
Recensione:
Indirizzi per estratti:
Citazione:
S. Morris et al., "THE COST-EFFECTIVENESS OF CLOZAPINE - A SURVEY OF THE LITERATURE", Clinical drug investigation, 15(2), 1998, pp. 137-152

Abstract

Treatment-resistant schizophrenia is a severely debilitating and costly disease. While clozapine is reported to be an effective therapy fortreatment-resistant schizophrenia, it is nevertheless largely underutilised. A review of published cost-effectiveness studies of clozapine conducted in the USA, UK, Sweden and Canada, and employing a variety of study designs, reveals consistent reporting of clinical efficacy, cost and cost-effectiveness findings in favour of clozapine over conventional antipsychotics in the management of treatment-resistant schizophrenia. All reported economic evidence indicates that, despite its higher acquisition cost, clozapine nevertheless represents cost-effective therapy for treatment-resistant schizophrenia. Furthermore, the evidence indicates that, for many patients, clozapine may substantially reduce costs associated with treatment-resistant schizophrenia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:05:46